AUROVELA 24 FE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Aurovela 24 Fe, and what generic alternatives are available?
Aurovela 24 Fe is a drug marketed by Aurobindo Pharma and is included in one NDA.
The generic ingredient in AUROVELA 24 FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AUROVELA 24 FE?
- What are the global sales for AUROVELA 24 FE?
- What is Average Wholesale Price for AUROVELA 24 FE?
Summary for AUROVELA 24 FE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 3 |
DailyMed Link: | AUROVELA 24 FE at DailyMed |
US Patents and Regulatory Information for AUROVELA 24 FE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aurobindo Pharma | AUROVELA 24 FE | ethinyl estradiol; norethindrone acetate | TABLET;ORAL | 207504-001 | Jun 15, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |